The rapid evolution of commercial marketing has shifted consumer reliance from traditional billboards to digital-first endorsements. In the Philippine jurisdiction, the legal landscape surrounding product endorsees—ranging from high-profile celebrity brand ambassadors to micro-influencers—has adjusted accordingly. While corporate entities traditionally shoulder the brunt of defective product suits, individuals who leverage their public trust to promote commercial goods or services are increasingly facing legal exposure.
I. The Statutory Anchor: The Consumer Act of the Philippines (R.A. 7394)
The primary legislative mechanism safeguarding consumers against deceptive marketing is Republic Act No. 7394, otherwise known as the Consumer Act of the Philippines.
Prohibition of False and Deceptive Advertisements
Under Article 110 of R.A. 7394, it is explicitly declared unlawful for any person to disseminate or cause the dissemination of any false, deceptive, or misleading advertisement by any medium for the purpose of inducing the purchase of consumer products or services.
Statutory Definition (Article 4): "Advertisement" means the prepared and through any form of mass medium, subsequently applied, disseminated or circulated advertising matter. "Advertising" covers the presentation of facts, data, or information regarding the attributes, features, quality, or availability of consumer products.
Scope of Liability for Endorsers
While the law outlines specific protections for media publishers and broadcasters (exempting them from liability if they provide the identity of the advertiser upon request), product endorsees do not enjoy the same blanket statutory immunity. If an endorsee actively misrepresents the quality, efficacy, safety, or regulatory approval of a product, they can be interpreted under the law as a party who "caused the dissemination" of a deceptive advertisement.
- Quasi-Strict Liability Regimes: For specialized items like food, drugs, cosmetics, and medical devices, Article 112 mandates that no person shall advertise such goods in a manner that creates an erroneous impression regarding their safety, character, or merit.
- The Burden of Proof: Once an administrative body or court identifies a prima facie case of false advertising, the burden of proof shifts significantly to the defense to prove the veracity of the claim, presenting high exposure to an unprepared endorser.
II. Enhanced Regulatory Frameworks: DTI and FDA Mandates
As online endorsements have multiplied, administrative agencies have weaponized their rule-making powers to impose strict obligations directly onto endorsees.
1. Department of Trade and Industry (DTI) Guidelines
The DTI actively monitors digital commerce and influencer advertising. Under existing consumer protection rules, the DTI enforces a strict policy on the Disclosure of Material Connections.
- Mandatory Transparency: Endorsers must explicitly disclose if a post, video, or review is a paid partnership, sponsored content, or the result of free samples/gifts.
- Conspicuous Placement: Disclosures must be clear, legible, and proximate to the endorsement claim (e.g., avoiding concealment beneath "see more" tabs or deeply embedded within unrelated hashtags). Failure to disclose these connections transforms an ostensibly independent opinion into a deceptive sales practice.
2. Food and Drug Administration (FDA) Oversight
The FDA exercises jurisdiction under R.A. 9711 (The Food and Drug Administration Act of 2009). Product endorsees face severe legal risks when promoting health and wellness lines:
- Unregistered Products: It is illegal to advertise or endorse any health product (including skincare, slimming supplements, and organic food lines) that lacks a valid Certificate of Product Registration (CPR) or notification from the FDA.
- False Therapeutic Claims: Endorsers who read scripts guaranteeing "miracle cures" or untruthful medical benefits ("No Approved Therapeutic Claims" violations) can be held administratively liable, resulting in product seizures and heavy institutional fines.
III. Civil Tort Liability and Criminal Accountability
Beyond administrative sanctions from the DTI or FDA, a misleading or harmful endorsement can trigger actions within regular trial courts.
Civil Liability: Quasi-Delict (Article 2176, Civil Code)
Under the Civil Code of the Philippines, an endorsee who fails to perform basic due diligence before promoting a harmful product can be sued for damages under the doctrine of Quasi-Delict (tortious negligence).
- If an endorsee asserts personal knowledge of a product's safety (e.g., claiming a chemical hair treatment is "100% safe for pregnant women"), and that claim causes physical injury or property damage to a consumer, the endorsee’s reckless statement satisfies the elements of actionable negligence.
- The injured consumer may file a civil suit for actual, moral, and exemplary damages, alongside attorney's fees.
Criminal Liability: "Other Deceits" (Article 318, Revised Penal Code)
In egregious cases where an endorsee knowingly participates in a fraudulent scheme—such as promoting a confirmed counterfeit luxury brand, a fraudulent investment vehicle, or a predatory lending application—the endorsee can be treated as a co-conspirator or principal by indispensable cooperation under Article 318 of the Revised Penal Code (Other Deceits) or under the swindling statutes (Estafa).
IV. Legal Risk Allocation Matrix
| Liability Dimension | Product Manufacturer / Brand Owner | Product Endorsee / Influencer |
|---|---|---|
| Strict Product Liability | Primary liable party for manufacturing defects, design flaws, and inherent product hazards. | Not liable for hidden manufacturing defects unless they explicitly guaranteed those facets. |
| False Representation | Fully liable for creating false product narratives, unsubstantiated data, and illegal scripts. | Jointly liable if they amplify unverified claims or state personal experiences that are intentionally fabricated. |
| Concealment of Commercial Intent | Accountable for failing to provide appropriate ad tagging mechanisms. | Directly liable for presenting paid advertisements as organic, unbiased personal opinions. |
| Regulatory Compliance (FDA/DTI) | Responsible for acquiring permits, CPRs, and sales promotion clearances. | Liable if they promote products despite knowing (or failing to verify) that the brand lacks valid regulatory permits. |
V. Mitigating Liability: Legal Due Diligence for Endorsers
To avoid administrative fines, civil damages, or reputational destruction, product endorsees must adopt defensive legal protocols before executing a talent or promotion contract:
- Exercise Due Diligence: Endorsers must verify the regulatory standing of the client. They should request copies of the brand's DTI registration, SEC papers, and relevant FDA Certificates of Product Registration.
- Review and Substantiate Claims: Scripted claims—especially regarding health, financial returns, or technical performance—must be backed by clinical studies, certifications, or verified data provided by the brand.
- Incorporate Robust Contractual Indemnification: Endorsement agreements must contain robust indemnity clauses stating that the brand owner shall hold the endorsee free and harmless from any third-party civil, administrative, or criminal claims arising from product defects or corporate misrepresentations.
- Adhere to Self-Regulatory Codes: Endorsers should cross-reference campaigns with the Advertising Standards Council (ASC) Code of Ethics, which outlines the baseline parameters for truthfulness, disparagement prevention, and consumer transparency in the Philippines.